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A b s t r a c t
Background: Many researchers have studied age- and sex-related differences in the management of patients with coronary 
artery disease. However, the results are inconsistent.
Aim: To assess sex- and age-related bias in the secondary prevention in patients hospitalised due to ischaemic heart disease. 
Methods: Five hospitals with departments of cardiology serving a city and surrounding districts in southern Poland participated 
in the study. Consecutive patients hospitalised from 1 April 2005 to 31 July 2006 due to acute coronary syndrome or for a myo-
cardial revascularisation procedure and aged £ 80 years were recruited and interviewed 6–18 months after hospitalisation.
Results: The hospital records of 640 patients were reviewed and 513 (80.2%) patients participated in the follow-up interview. 
Women were older and less educated than their male counterparts. Sex was not independently associated with the control of 
major risk factors in the post-discharge period, whereas age was related to a higher probability of having high blood pressure 
and a lower chance of smoking. Multivariate analysis showed that females were prescribed calcium antagonists (odds ratio 
[OR] 2.13; 95% confidence intervals [CI] 1.34–3.39) and diuretics (OR 1.52; 95% CI 1.00–2.31) more often than males. Age 
was independently related to the prescription rate of diuretics (≥ 70 years vs. < 60 years; OR 1.61; 95% CI 1.19–2.20). The 
prescription rate of antiplatelets, beta-blockers, angiotensin converting enzyme-inhibitors/sartans, lipid-lowering drugs, and 
anticoagulants was not related to age or sex. 
Conclusions: We found no major sex-related difference in the frequency of achieving recommended goals in secondary 
prevention, whereas age was related to a lower prevalence of smoking and a higher probability of having high blood pressure 
in subjects after hospitalisation for coronary artery disease. 
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INTRODUCTION
Coronary artery disease (CAD) is the most common single 
cause of death in developed countries. According to European 
Society of Cardiology guidelines, preventive interventions 
aimed at patients with cardiovascular disease have been 
ranked as the highest priority [1].
Numerous studies have analysed the different manage-
ment practices in men and women with acute coronary syn-
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dromes [2–7]. Recently, several studies concerning sex-related 
differences in CAD management have been published [8–12]. 
Some [2–4, 9], but not all [5, 10, 11], of these studies showed 
that women are examined and treated less aggressively than 
men. Moreover, some analyses have indicated that the prog-
nosis of women with ischaemic heart disease (IHD) is worse 
compared to their male counterparts [3, 4, 9]. However, 
other investigators have found no gender-related differences 
in cardiovascular risk in patients with CAD [5, 8, 10, 13–15]. 
It has also been suggested that differences in mortality, al-
though present in univariate analysis, disappear after multiple 
adjustments [6, 7, 16–18]. Several analyses have shown an 
even higher risk in men [2, 19]. It has also been suggested 
that women were less likely than men to accept a physician’s 
recommendation for any intervention [20].
Age is one of the most important factors determining the 
prognosis of patients with CAD [1, 15, 18]. Nevertheless, it 
has been shown that older people are often treated less ag-
gressively [21–23]. Narrowing the gap between recommended 
therapy and actual practice in this population remains vitally 
important, because the population of older adults is rapidly 
growing and because cardiovascular disease is the leading 
cause of morbidity and mortality in the elderly. 
The main goal of the Cracovian Program for Secondary 
Prevention of Ischaemic Heart Disease was to assess and im-
prove the quality of clinical care in the secondary prevention 
of CAD in Krakow [24–26]. Subsequently, the same hospitals 
took part in the European Action on Secondary Prevention 
through Intervention to Reduce Events (EUROASPIRE) surveys 
which were conducted under the auspices of the European 
Society of Cardiology (ESC). The surveys showed that there 
was considerable potential for further improvement in second-
ary prevention in European countries [27], including Polish 
hospitals [25, 26]. 
We used data from hospitals who had participated in the 
Cracovian Program for Secondary Prevention of Ischaemic 
Heart Disease and the EUROASPIRE surveys to estimate sex- 
and age-related differences in the secondary prevention in 
patients hospitalised due to IHD in Krakow [24–26].
METHODS
The groups analysed in the study and the methods used in 
the Cracovian Program for Secondary Prevention of Ischaemic 
Heart Disease have been described in earlier reports [24–26]. 
A brief description is given below. 
Five hospitals with departments of cardiology serving 
Krakow (a city in the south Poland) and surrounding districts 
participated in the study. The total population of this area 
was around 1,200,000. In each department, we reviewed the 
medical records of consecutive patients aged £ 80 years and 
hospitalised between 1 April 2005 and 31 July 2006 with the 
following discharge diagnosis or procedures: 
 — acute myocardial infarction (first or recurrent, no prior 
percutaneous coronary intervention [PCI] or coronary 
artery bypass grafting [CABG])
 — unstable angina (first or recurrent, no prior PCI or CABG)
 — elective or emergency PCI (first, no prior CABG)
 — elective or emergency coronary artery bypass surgery 
(first).
Patients were identified retrospectively. We did not in-
clude data of patients undergoing CABG and valve surgery 
during the same procedure. Those who died during their 
in-hospital stay were excluded from the analysis. If a patient 
was hospitalised more than once during the study period, 
only the first hospitalisation was regarded as an index event. 
All medical records were reviewed by trained reviewers using 
a standardised data collection form that included information 
about demographics, personal cardiac history, coronary risk 
factors, and medications.
The study participants were invited to take part in a fol-
low-up examination 6–18 months after discharge. A standard 
questionnaire was used to obtain data on the patient’s de-
mographic characteristics, personal history of IHD, smoking 
status, blood pressure, fasting glucose, plasma lipids, and 
prescribed medications. The patient’s height and weight were 
measured in a standing position without shoes and heavy 
outer garments using standard scales with a vertical ruler. The 
patient’s body mass index (BMI) was calculated according to 
the following formula: BMI = weight [kg]/(height [mL])2. The 
patient’s blood pressure was measured twice from the upper 
right arm in a sitting position after at least 5 min of rest. For 
plasma lipid and glucose measurements, a fasting venous 
blood sample was taken between 7.30 and 8.30 a.m. We used 
for the present report the results of analyses conducted no later 
than 4 h after the blood collection. The analyses were carried 
out using enzymatic automated methods. The study protocol 
was approved by the Bioethics Committee of the Institution.
Statistical analysis
The categorical variables are reported as percentages and 
continuous variables as means ± standard deviation. The Pear-
son c2 test was applied to all categorical variables. Normally 
distributed continuous variables were compared using the 
Student’s t test, whereas variables without normal distributions 
were compared using the Mann-Whitney U test. Categorical 
variables were compared using the c2 test (or Wilcoxon test 
when appropriate). The correlations were evaluated using the 
Spearman rank correlation. A two-tailed p value of less than 
0.05 was regarded as indicating statistical significance. Mul-
tivariate logistic analysis was used to assess the independent 
influence of age and sex on the probability of a patient being 
prescribed a cardiovascular drug, as well as the probability of 
the patient having a risk factor controlled. All variables from 
Table 1 were included in the multivariate model.
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RESULTS
The hospital records of 640 patients were reviewed. The 
clinical characteristics of the study population are presented 
in Table 1. Two hundred and seventy two (42.5%) patients 
were < 60 years of age, 243 (38.0%) were 60–70 years, and 
125 (19.5%) were ≥ 70 years. The patients qualified for 
CABG were significantly older than the other groups (CABG 
64.0 ± 8.0 years; PCI 59.6 ± 9.2 years; myocardial infarc-
tion 60.6 ± 9.2 years; unstable angina 61.0 ± 8.6). Patients 
hospitalised in university and community hospital depart-
ments were of a similar age (60.9 ± 9.1 vs. 61.2 ± 8.8 years, 
p = NS). The patient’s age correlated with the patient’s 
duration of education (r = –0.17, p < 0.05), but not with 
the mean time between the index hospitalisation and the 
follow-up examination (r = –0.05, p = NS). Patients who 
were active professionally at the time of the follow-up ex-
amination were younger compared to the rest of the study 
group (55.4 ± 7.4 vs. 63.9 ± 8.3 years, p < 0.0001). No 
correlation was found between the outpatient setting and age 
(hospital outpatient clinic 60.8 ± 9.0 years, general practi-
tioner 62.0 ± 9.3 years, private cardiologist 60.8 ± 7.9 years, 
no regular health check-up 62.4 ± 7.9 years; all comparisons 
were statistically not significant). 
Univariate analysis showed that women were prescribed 
calcium antagonists and diuretics at discharge from hospital 
more frequently than men (Table 2). After multivariate adjust-
ments, sex turned out to be independently related to the pre-
scription rate of calcium antagonists (Table 3). Age was related 
to the prescription rates of calcium antagonists, diuretics and 
antidiabetic drugs (Table 2). Multivariate analysis confirmed 
that an age of 60–70 years was related to a higher probability 
of being prescribed calcium antagonists, diuretics and anti-
diabetic drugs compared to younger subjects (Table 3). Older 
patients (age ≥ 70 years) also had a higher probability of being 
prescribed a diuretic. On the other hand, in older patients, 
the probability of being prescribed a beta-blocker was lower. 
The prescription rate of antiplatelets, angiotensin converting 
enzyme-inhibitors (ACE)-inhibitors/sartans, lipid-lowering 
drugs, and anticoagulants was not related to age or sex.
Out of a total of 640 recruited patients, 513 (80.2%) 
participated in the follow-up examination (1.1 ± 0.4 years 
after discharge on average). The participation rate did not dif-
fer significantly between men and women (79.9% vs. 83.2%, 
p = NS) nor between age groups (79.4% vs. 79.0% vs. 84.0% 
for patients at age < 60 years, 60–70 years, and ≥ 70 years, 
respectively, p = NS). The time from the patient’s discharge to 
the follow-up examination did not differ significantly between 
either sex or age groups. 
At the follow-up examination, women and older 
participants had blood pressure levels that were below 
Table 1. Characteristics of the patients participating in the study
Women (n = 185) Men (n = 455) P Total (n = 640)
Age [years] 62.4 ± 8.9 60.5 ± 8.9 < 0.05 61.1 ± 8.9
Category:
Myocardial infarction
Unstable angina
PCI
CABG
30.3%
33.5%
21.1%
15.1%
21.8%
25.1%
32.5%
20.7%
< 0.05
24.2%
27.5%
29.2%
19.1%
Type of hospital:
Teaching
District
32.4%
67.6%
48.3%
51.9%
< 0.05
43.6%
56.4%
Mean time between index hospitalisation and 
follow-up examination [years]*
1.1 ± 0.3 1.1 ± 0.4 NS 1.1 ± 0.4
Mean duration of education [years]* 10.8 ± 3.5 12.1 ± 3.4 < 0.05 11.7 ± 3.5
Outpatient setting*:
Hospital outpatient clinic
General practitioner
Private cardiologist
No physician
53.3%
31.8%
11.7%
3.3%
51.8%
34.3%
10.9%
3.1%
NS
52.2%
33.5%
11.1%
3.1%
Professionally active*:
Yes
No
17.7%
82.3%
37.3%
62.7%
< 0.05
31.4%
68.6%
*Available only for those who attended the follow-up examination (154 women and 359 men); PCI — percutaneous coronary intervention;  
CABG — coronary artery bypass grafting
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140/90 mm Hg (Table 4) less frequently. After multivariate ad-
justments, age remained significantly related to the frequency 
of high blood pressure (Table 5). Sex was not independently 
related to the control of any major risk factor. The prescrip-
tion rates 6–18 months after hospitalisation according to 
sex and age groups are presented in Table 6. Females were 
prescribed diuretics and calcium antagonists more frequently 
in both the univariate and multivariate analyses (Table 7). 
Age was independently related to the prescription rate of 
diuretics. The prescription rate of antiplatelets, beta-blockers, 
ACE-inhibitors/sartans, lipid-lowering drugs, and anticoagu-
lants was not related to age or sex.
Table 2. Prescription rates at discharge by age and sex
AP BB ACEI/S CA D LLD AC AD
Men
Women
p
98.0%
96.8%
NS
89.7%
89.7%
NS
88.6%
88.6%
NS
17.4%
31.9%
< 0.0001
32.8%
43.2%
< 0.05
96.0%
94.6%
NS
4.2%
4.3%
NS
21.8%
23.8%
NS
Age [years]
< 60
60–70
≥ 70
p
97.4%
97.1%
99.2%
NS
92.7%
88.5%
85.6%
NS
87.5%
89.3%
89.6%
NS
14.7%
28.0%
24.0%
< 0.0001
26.1%
42.0%
44.8%
< 0.0001
96.3%
95.1%
95.2%
NS
3.7%
4.5%
4.8%
NS
16.9%
26.3%
26.4%
< 0.05
Total 97.7 89.7 88.6 21.6 35.8 95.6 4.2 22.3
AP — antiplatelets; BB — beta-blockers; ACEI/S — angiotensin converting enzyme inhibitors/sartans; CA — calcium antagonists; D — diuretics; 
LLD — lipid lowering drugs; AC — anticoagulants; AD — antidiabetic agents
Table 3. Odds ratios (95% confidence intervals) of being prescribed a drug at discharge by age and sex
AP BB ACEI/S CA D LLD AC AD
Sex*:
Men
Women
1.00
0.67  
(0.23–1.97)
1.00
1.07  
(0.60–1.90)
1.00
0.90  
(0.52–1.57)
1.00
2.22  
(1.48–3.35)
1.00
1.37  
(0.95–1.97)
1.00
0.76  
(0.34–1.72)
1.00
0.97  
(0.41–2.29)
1.00
1.01  
(0.67–1.53)
Age [years]**:
< 60
60–70
≥ 70
1.00
1.01  
(0.31–3.24)
1.80  
(0.62–5.25)
1.00
0.53  
(0.28–0.99)
0.66  
(0.47–0.94)
1.00
1.19  
(0.68–2.08)
1.15  
(0.81–1.63)
1.00
2.14  
(1.36–3.38)
1.30  
(0.98–1.71)
1.00
1.93  
(1.31–2.84)
1.51  
(1.20–1.90)
1.00
0.78  
(0.32–1.89)
0.99  
(0.57–1.72)
1.00
1.31  
(0.53–3.19)
1.13  
(0.66–1.94)
1.00
1.75  
(1.12–2.72)
1.29  
(0.99–1.68)
*adjusted for age, diagnostic category, and type of hospital; **adjusted for sex, diagnostic category, and type of hospital; abbreviations as in Table 2
Table 4. Risk factor control rates 6–18 months after hospitalisation by age and sex
Non-smoking BP < 140/90 mm Hg LDL-C < 2.5 mmol/L FG < 7.0 mmol/L BMI < 30 kg/m2
Men
Women
p
78.3%
85.1%
NS
54.8%
44.7%
< 0.05
61.8%
56.7%
NS
85.5%
90.7%
NS
68.3%
64.1%
NS
Age [years]:
< 60
60–70
≥ 70
p
67.1%
86.5%
96.2%
< 0.0001
60.7%
46.6%
43.3%
< 0.01
57.7%
61.1%
64.1%
NS
87.1%
85.8%
89.3%
NS
62.7%
70.7%
68.9%
NS
Total 80.3 51.8 60.3 87.2 67.0
BP — blood pressure; LDL-C — low density lipoprotein; FG — fasting glucose; BMI — body mass index
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Finally, we compared the prescription rates at discharge 
and at the time of the follow-up interview. The prescription 
rate of antiplatelets, ACE inhibitors/sartans and lipid lowering 
drugs decreased (all p < 0.001), whereas the prescription rate 
of beta-blockers (p = 0.08), calcium antagonists (p = 0.72), 
diuretics (p = 0.74), anticoagulants (p = 0.074), and antidia-
betic drugs (p = 0.69) did not change significantly. 
DISCUSSION
Recruiting coronary patients hospitalised in all city hospi-
tals with departments of cardiology, we were able to show 
no major sex- or age-related bias in the quality of medical 
care in secondary prevention of CAD. We used goals from 
the ESC 2003 guidelines [28] as cut-off values because we 
recruited subjects hospitalised in 2005–2006, whereas the 
Table 5. Odds ratios (95% confidence intervals) of risk factor control 6–18 months after hospitalisation by age and sex
Non-smoking BP < 140/90 mm Hg LDL-C < 2.5 mmol/L FG < 7.0 mmol/L BMI < 30 kg/m2
Sex*:
Men
Women
1.00
1.41 (0.80–2.48)
1.00
0.78 (0.52–1.17)
1.00
0.84 (0.56–1.27)
1.00
1.67 (0.87–3.20)
1.00
0.86 (0.56–1.31)
Age [years]**
< 60 
60–70 
≥ 70
1.00
3.03 (1.77–5.21)
3.88 (2.25–6.68)
1.00
0.61 (0.40–0.93)
0.76 (0.59–0.98)
1.00
1.09 (0.71–1.66)
1.21 (0.93–1.58)
1.00
0.88 (0.48–1.61)
1.22 (0.81–1.83)
1.00
1.53 (0.98–2.38)
1.21 (0.92–1.58)
*adjusted for age, years of education, professional activity, diagnostic category, type of hospital, outpatient setting, and time between index 
hospitalisation and follow-up; **adjusted for sex, years of education, professional activity, diagnostic category, type of hospital, outpatient setting, 
and time between index hospitalisation and follow-up; abbreviations as in Table 4
Table 6. Prescription rates 6–18 months after hospitalisation by age and sex
AP BB ACEI/S CA D LLD AC AD
Men
Women
p
90.7%
88.2%
NS
89.1%
82.5%
< 0.05
79.2%
78.6%
NS
17.7%
32.5%
< 0.001
30.6%
43.5%
< 0.01
87.1%
81.7%
NS
7.3%
4.6%
NS
21.6%
22.1%
NS
Age [years]:
< 60
60–70
≥ 70
p
89.7%
90.5%
89.5%
NS
89.8%
84.3%
86.7%
NS
79.0%
80.1%
77.4%
NS
17.7%
25.1%
25.7%
NS
25.7%
38.7%
44.8%
< 0.01
86.9%
88.4%
77.1%
< 0.05
4.7%
8.4%
6.7%
NS
17.8%
20.4%
32.4%
< 0.05
Total 90.0 87.1 79.0 22.1 34.5 85.5 6.5 21.8
Abbreviations as in Table 2
Table 7. Odds ratios (95% confidence intervals) of being prescribed a drug 6–18 months after hospitalisation by age and sex
AP BB ACEI/S CA D LLD AC AD
Sex*:
Men
Women
1.00
0.77  
(0.40–1.46)
1.00
0.64  
(0.36–1.14)
1.00
1.04  
(0.64–1.71)
1.00
2.13  
(1.34–3.39)
1.00
1.52  
(1.00–2.31)
1.00
0.71  
(0.40–1.23)
1.00
0.51  
(0.21–1.24)
1.00
0.97  
(0.59–1.59)
Age [years]**:
< 60 
60–70
≥ 70
1.00
0.98  
(0.62–1.54)
1.10  
(0.52–2.31)
1.00
0.97  
(0.55–1.69)
0.85  
(0.59–1.22)
1.00
1.19  
(0.68–2.08)
1.15  
(0.81–1.63)
1.00
1.64  
(0.95–2.86)
1.27  
(0.90–1.80)
1.00
1.86  
(1.15–3.01)
1.61  
(1.19–2.20)
1.00
1.10  
(0.55–2.19)
0.62  
(0.42–1.92)
1.00
2.26  
(0.89–5.71)
1.14  
(0.64–2.02)
1.00
1.19  
(0.67–2.10)
1.39  
(1.00–1.91)
*adjusted for age, years of education, professional activity, diagnostic category, type of hospital, outpatient setting, and time between index 
hospitalisation and follow-up; **adjusted for sex, years of education, professional activity, diagnostic category, type of hospital, outpatient setting, 
and time between index hospitalisation and follow-up; abbreviations as in Table 2
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follow-up interviews took place in 2006 and from January 
to March 2007 (thus prior to the publication of the ESC 
2007 guidelines). 
It is widely believed that women are on average ten 
years older at the time of developing cardiovascular disease. 
In our study population, the mean age of women was higher 
only by two years compared to men. Several factors could 
reduce this difference. Firstly, we recruited subjects after 
a first coronary event as well as subjects who had experienced 
a recurrent event. It can be assumed that a sex-based differ-
ence in age is much smaller in patients with a long history of 
CAD. Secondly, we excluded all patients aged over 80. As the 
majority of CAD patients aged 80 years or more are females, 
this criterion could indeed reduce the difference in the mean 
age between sexes. Thirdly, due to an increased number of 
co-morbidities, older patients are less likely to undergo CABG. 
Indeed, relatively fewer women were in the CABG group. 
Fourthly, the difference in the mean age at the time of the first 
manifestation of cardiovascular disease is now decreasing, as 
has been shown recently [29].
The common belief that women are underdiagnosed 
and undertreated may be due to atypical early symptoms, 
often ambiguous diagnostic test results, and the widespread 
belief that cardiovascular disease occurs more frequently in 
men [30, 31]. The results of the present study suggest that the 
sex-based bias in secondary prevention is not a major problem 
in departments of cardiology in the city where the study was 
done. We found no significant difference in the prescription 
rates of cardiovascular medications between women and 
men, with the exception of diuretics and calcium antagonists, 
which were prescribed more often to women. Indeed, the 
most interesting finding of the present analysis is that women 
with CAD were prescribed certain cardiovascular drugs more 
frequently than their male counterparts. This may be due 
to a higher proportion of women with severe hypertension. 
It is widely accepted that older females have hypertension 
more frequently, and that the course of hypertension is 
more serious in elderly females compared to males [32]. 
Unfortunately, we have no data on the number of patients 
with 1st, 2nd, or 3rd gra de hypertension. In the past, numerous 
studies have been published indicating a somewhat lower 
probability of being prescribed cardiovascular drugs among 
women with IHD [2, 9, 33–35]. No major influence of sex 
was also reported [36, 37]. Recently, Dallongeville et al. [38] 
studied data from 22 European countries and showed results 
similar to ours on the prescription rates of calcium antagonists 
and diuretics in men and women. Our present results are in 
accordance with the data from the Cracovian Program for 
Secondary Prevention of Ischaemic Heart Disease which were 
obtained several years earlier [39].
Our results confirm that in recent decades there has 
been a significant improvement in the approach to secondary 
prevention of IHD in women. It seems that nowadays there 
is no significant sex-based difference in cardiovascular pre-
vention. As hospitals from only one university city took part 
in the survey, the existence of a sex-based bias in secondary 
prevention in other regions of the country cannot be ruled out. 
It should also be stressed that control of the most important 
risk factors is insufficient in both men and women, and that 
the improvement in this area, if detectable, is very slow [24, 
26, 40]. It is important to make further progress in the imple-
mentation of secondary prevention in everyday practice [41].
Previously published studies have indicated that the 
quality of medical care is related to the patients’ age and that 
the prescription rates of cardioprotective drugs and that the 
control of risk factors is lower in aged subjects [21–23]. Our 
results show that in the city where the survey was carried out, 
age does not influence the quality of medical care in second-
ary prevention: rates of hyperglycaemia, high cholesterol level 
and obesity were similar across all age groups. On the other 
hand, age was related to the control of hypertension, but 
this can probably be explained by the increasing prevalence 
of hypertension with age as well as by more severe forms 
of hypertension and the difficulties of treating high blood 
pressure that are specific to elderly patients, rather than by 
a lower quality of medical care. Indeed, the prescription rates 
of diuretics were even higher in older participants compared 
to subjects below 60 years of age. This finding is consistent 
with the current guidelines [1].
We did not find any significant relation between age or 
sex and the prescription rate of antiplatelets, beta-blockers, 
drugs interfering with the renin–angiotensin system or 
lipid-lowering drugs. Indeed, our results suggest that the pre-
scription rates of cardiovascular drugs with the biggest number 
of scientific proofs showing their beneficial effect on survival 
in CAD patients are not influenced by the patients’ age or sex. 
We found the control of hypercholesterolaemia to be 
much better compared to the high risk subgroup of the 
3ST-POL study population [42]. However, important differ-
ences between the studies should be underlined. Śliż et al. 
[42] analysed ambulatory patients, whereas we recruited 
subjects hospitalised due to CAD. Indeed, the quality of the 
hypercholesterolaemia management during hospitalisation 
is the most important factor related to lipid management 
in the post-discharge period [43]. Moreover, Śliż et al. [42] 
defined high risk patients as those who have CAD, diabetes 
or SCORE ≥ 5, whereas we analysed only coronary patients. 
Limitations of the study
Our study does have some limitations. The first is that we 
were not able to assess the risk of cardiovascular complica-
tions. Second, there may have been some unrecognised 
differences in the subgroups handled by particular hospitals 
or across diagnostic groups which might have influenced the 
approach to secondary prevention. Third, groups analysed in 
the study were not representative of all CAD patients as they 
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were limited to patients who were hospitalised for acute CAD 
events or for revascularisation procedures. Therefore, it should 
be stressed that our results should not be directly applied to 
coronary patients who do not have a history of hospitalisation 
due to IHD or to those living in other parts of Poland.  
CONCLUSIONS
We found no major sex-related difference in achieving the 
recommended goals in secondary prevention, whereas age 
was related to a lower prevalence of smoking and a higher 
probability of having high blood pressure in subjects after 
hospitalisation due to CAD. 
The study was supported by a grant from the Polish Ministry of 
Science and Higher Education No 2 pO5D 008 30.
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S t r e s z c z e n i e
Wstęp: W ostatnich latach opublikowano wiele analiz, w których oceniano związek między wiekiem i płcią pacjenta a ja-
kością opieki medycznej u osób z chorobą niedokrwienną serca. Jednak wyniki badań nie są zgodne. Część wskazuje, że 
różnica zależna od płci jest spowodowana bardziej zaawansowanym wiekiem i innym profilem czynników ryzyka kobiet 
w porównaniu z mężczyznami. 
Cel: Celem pracy była ocena wpływu wieku i płci na częstość stosowania leków o działaniu kardioprotekcyjnym oraz na 
częstość kontroli głównych czynników ryzyka u pacjentów po hospitalizacji z powodu ostrego zespołu wieńcowego (OZW) 
lub w celu rewaskularyzacji mięśnia sercowego. 
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Metody: Do badania kwalifikowano kolejnych pacjentów w wieku £ 80 lat hospitalizowanych na 5 oddziałach kardiologicznych 
krakowskich szpitali od 1 kwietnia 2005 r. do 31 lipca 2006 r. z powodu OZW lub w celu rewaskularyzacji mięśnia serco-
wego. Osoby te zostały zaproszone do badania w okresie 6–18 miesięcy po wypisie ze szpitala. Na podstawie dokumentacji 
szpitalnej oceniono częstość zalecania przy wypisie ze szpitala podstawowych grup leków o działaniu kardioprotekcyjnym, 
a także częstość ich stosowania i kontrolę głównych czynników ryzyka w 6–18 miesięcy po wypisie. 
Wyniki: Do badania zakwalifikowano 640 pacjentów, a do badania w 6–18 miesięcy po wypisie ze szpitala zgłosiło się 
513 (80,2%) osób. Kobiety były starsze niż mężczyźni (62,4 ± 8,9 vs. 60,5 ± 8,9 roku; p < 0,05). Płeć żeńska wiązała się 
z większym prawdopodobieństwem zalecenia leku z grupy antagonistów wapnia przy wypisie ze szpitala [iloraz szans (OR) 
2,22; 95% przedziały ufności (CI) 1,48–3,35], natomiast wiek z częstością zalecania antagonistów wapnia (≥ 60 vs. < 60 lat; 
OR 2,14; 95% CI 1,36–3,38) i diuretyków (≥ 70 vs. < 60 lat; OR 1,51; 95% CI 1,25–1,90). Z kolei w 6–18 miesięcy po 
hospitalizacji płeć wiązała się z częstością stosowania antagonistów wapnia (OR 2,13; 95% CI 1,34–3,39) oraz diuretyków 
(OR 1,52; 95% CI 1,00–2,31), natomiast wiek jedynie z częstością stosowania diuretyków (≥ 70 vs. < 60 lat; OR 1,61;  
95% CI 1,19–2,20). Częstość stosowania leków przeciwpłytkowych, leków beta-adrenolitycznych, inhibitorów enzymu kon-
wertującego angiotensynę lub sartanów, leków hipolipemizujących i antykoagulantów nie wiązała się z wiekiem lub płcią. Płeć 
nie była istotnie związana z częstością właściwej kontroli czynników ryzyka, natomiast wiek korelował z częstością niepale-
nia (≥ 70 vs. < 60 lat; OR 3,88; 95% CI 2,25–6,68) i częstością ciśnienia tętniczego < 140/90 mm Hg (≥ 70 vs. < 60 lat;  
OR 0,76; 95% CI 0,59–0,98). 
Wnioski: W grupie osób po hospitalizacji z powodu OZW lub w celu rewaskularyzacji mięśnia sercowego nie stwierdzono 
zależnych od płci istotnych różnic w jakości opieki medycznej w zakresie wtórnej prewencji choroby niedokrwiennej serca. 
Wiek korelował z rzadszym paleniem tytoniu i gorszą kontrolą ciśnienia tętniczego, co może się wiązać z częstszym wystę-
powaniem umiarkowanego i ciężkiego nadciśnienia w starszych grupach wiekowych. 
Słowa kluczowe: choroba niedokrwienna serca, czynniki ryzyka, wtórna prewencja, wiek, płeć
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